Delisting Determination, The Nasdaq Stock Market, LLC,
November 8, 2019, Emmaus Life Sciences, Inc. The Nasdaq
Stock Market, Inc. (the Exchange) has determined to remove
from listing the common stock and warrant of Emmaus Life
Sciences, Inc. (the Company), effective at the opening of
the trading session on November 18, 2019. Based on review of
information provided by the Company, Nasdaq Staff determined
that the Company no longer qualified for listing on the Exchange
pursuant to Listing Rule 5110(a).
The Company was notified of the Staffs determination on
July 19, 2019.  The Company appealed the determination
to a Hearing Panel. Upon review of the information provided
by the Company, the Panel issued a decision dated
September 9, 2019, denying the Company continued listing
and notified the Company that trading in the Companys
securities would be suspended on September 11, 2019.
The Company did not request a review of the Panels decision
by the Nasdaq Listing and Hearing Review Council. The
Listing Council did not call the matter for review.
The Panels Determination to delist the Company
became final on October 24, 2019.